Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: The role of oxidative stress

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11906-11913

  Dong, Lan Feng ^a   Swettenham, Emma ^a   Eliasson, Johanna ^a   Wang, Xiu Fang ^a   Gold, Mikhal ^b   Medunic, Yasmine ^a   Stantic, Marina ^a   Low, Pauline ^a   Prochazka, Lubomir ^c   Witting, Paul K ^d   Turanek, Jaroslav ^c   Akporiaye, Emmanuel T ^b   Ralph, Stephen J ^a   Neuzil, Jiri ^a,e  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF ARIZONA   (United States)

^c VETERINARY RESEARCH INSTITUTE   (Czech Republic)

^d UNIVERSITY OF SYDNEY   (Australia)

^e INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHEROL SUCCINATE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER MODEL; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SELECTIVITY; ENDOTHELIUM CELL; FEMALE; IN VITRO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; ULTRASOUND; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA, MITOCHONDRIAL; DRUG RESISTANCE; ENDOTHELIUM, VASCULAR; HUMANS; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; VITAMIN E;

EID: 37549019351     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3034     Document Type: Article

References (51)

1. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7.
2. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
3. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87.
4. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93.
5. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
7. Albini A, Marchisone C, Del Grosso F, et al. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach. Am J Pathol 2000;156:1381-93.
8. Malecki M, Kolsut P, Proczka R. Angiogenic and antiangiogenic gene therapy. Gene Ther 2005;12:59-69.
9. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
10. Don AS, Kisker O, Dilda P, et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003;3:497-509.
11. Don AS, Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med 2004;10:372-8.
12. Fantin VR, Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006;25:4787-97.
13. Neuzil J, Dyason JC, Freeman R, et al. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 2007;39:65-72.
14. Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by a-tocopheryl succinate. Br J Cancer 2001;84:87-9.
15. Neuzil J, Weber T, Schröder A, et al. Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 2001;15:403-15.
16. Weber T, Dalen H, Andera L, et al. Mitochondria play a central role in apoptosis induced by α-tocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry 2003;42:4277-91.
17. Yu W, Sanders BG, Kline K. RRR-α-Tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res 2003;63:2483-91.
18. Stapelberg M, Gellert N, Swettenham E, et al. α-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J Biol Chem 2005;280:25369-76.
19. Swettenham E, Witting PK, Salvatore BA, Neuzil J. α-Tocopheryl succinate selectively induces apoptosis in neuroblastoma cells: potential therapy of malignancies of the nervous system? J Neurochem 2005;94:1448-56.
20. Weber T, Lu M, Andera L, et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo . Clin Cancer Res 2002;8:863-9.
21. Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery 2002;131:85-91.
22. Hahn T, Szabo L, Gold M, et al. Dietary administration of the proapoptotic vitamin E analogue α-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res 2006;66:9374-8.
23. Wang XF, Birringer M, Dong LF, et al. A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res 2007;67:3337-44.
24. Neuzil J, Schröder A, von Hundelshausen P, et al. Inhibition of inflammatory endothelial responses by a pathway involving caspase activation and p65 cleavage. Biochemistry 2001;40:4686-92.
25. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983;80:3734-7.
26. Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001;276:4588-96.
27. Wolter KG, Hsu YT, Smith CL, et al. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 2003;139:1281-92.
28. Guy CT, Webster MA, Schaller M, et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89:10578-82.
29. James AM, Sharpley MS, Manas AB, et al. Interaction of the mitochondria-targeted antioxidant mitoq with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem 2007;282:14708-18.
30. Sun F, Huo X, Zhai Y, et al. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell 2005;121:1043-57.
31. Albayrak T, Scherhammer V, Schoenfeld N, et al. The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction. Mol Biol Cell 2003;14:3082-96.
32. Dicker AP, Williams TL, Iliakis G, Grant DS. Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy. Am J Clin Oncol 2003;26:e45-53.
33. Pasquier E, Carre M, Pourroy B, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004;3:1301-10.
34. Marimpietri D, Nico B, Vacca A, et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 2005;24:6785-95.
35. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006;12:634-42.
36. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2006;64:1458-65.
37. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59-70.
38. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
39. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007;4:344-52.
40. Park SY, Chang I, Kim JY, et al. Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem 2004;279:7512-20.
41. Freeman R, Neuzil J. Role of thioredoxin-1 in apoptosis induction by α-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Lett 2006;580:2671-6.
42. Neuzil J, Widen C, Gellert N, et al. Mitochondria transmit apoptotic signals in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury. Redox Report 2007;12:148-62.
43. WAF1/CIP1. Proc Natl Acad Sci USA 2000;97:6427-32.
44. Hussain SP, Amstad P, He P, et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004;64:2350-6.
45. Higuchi M, Aggarwal BB, Yeh ET. Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest 1997;99:1751-8.
46. 0) yield insight into physiological mechanisms. FEBS Lett 1999;454:173-6.
47. Levraut J, Iwase H, Shao ZH, Vanden Hoek TL, Schumacker PT. Cell death during ischemia: relationship to mitochondrial depolarization and ROS generation. Am J Physiol 2003;284:H549-58.
48. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:1652-4.
49. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
50. Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res 2000;93:163-70.
51. Neuzil J, Swettenham E, Wang XF, Dong LF, Stapelberg M. α-Tocopheryl succinate inhibits angiogenesis by disrupting paracrine FGF2 signalling. FEBS Lett 2007;581:5611-5.